<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966299</url>
  </required_header>
  <id_info>
    <org_study_id>EryAdo</org_study_id>
    <nct_id>NCT04966299</nct_id>
  </id_info>
  <brief_title>Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents</brief_title>
  <acronym>EryAdo</acronym>
  <official_title>Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents: a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Childhood and adolescence are crucial periods for prevention of obesity, as obese children&#xD;
      are five times more likely to be obese at adulthood than lean children. To this purpose,&#xD;
      sugar consumption should be reduced. The sugar alcohol erythritol is increasingly popular as&#xD;
      sugar substitute in the food industry and is also recommended to diabetic patients. The&#xD;
      substance is freely available. Recent acute studies show that erythritol has a positive&#xD;
      influence on satiation and gastric emptying without affecting insulin and plasma glucose. In&#xD;
      this trial, the investigators aim to assess the effect of a chronic intake of erythritol&#xD;
      versus sucrose on insulin resistance in healthy adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to assess the effects of the daily intake of an erythritol-sweetened beverage&#xD;
      over 5 weeks on insulin resistance, glucose tolerance and metabolism as well as on gut&#xD;
      microbiota. Moreover, this study will also assess the effect of the above-mentioned&#xD;
      intervention on food intake, body composition and gastrointestinal tolerance in this&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Insulin resistance as measured by the HOMA Index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Insulin</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Insulin levels during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Glucose</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Glucose levels during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: C-Peptide</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>C-peptide levels during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Glucagon</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Glucagon levels during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Fructosamin</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Fructosamin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: HbA1C</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>HbA1C levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Continuous glucose monitoring average</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Continuous glucose monitoring for average glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Continuous glucose monitoring glucose variability</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Continuous glucose monitoring for glucose variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance: Continuous glucose monitoring time within range</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Continuous glucose monitoring for time within range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose absorption</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Glucose absorption measured by 3-OMG concetrations during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Metabolomics in plasma, urine and stool samples, measured by 1H-NMR and Liquid Chromatography-Mass Spectrometry (LC-MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota composition</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>The taxonomic and functional profiles of the gut microbiota (stool samples) assessed by metagenomic shotgun sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal hormones secretion: GLP-1</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Secretion of GLP-1 during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal hormones secretion: PYY</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Secretion of PYY during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal hormones secretion: Ghrelin</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Secretion of Ghrelin during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal hormones secretion: CCK</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Secretion of CCK during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Food intake assessed with self-reported food records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Change from baseline to 3 and 5 weeks after polyol/sucrose intake</time_frame>
    <description>Gastrointestinal tolerance recorded by the &quot;Gastrointestinal Symptoms Rating Scale&quot; (GSRS), 15 items rated on 7 Point Likert-Scale, a higher score means a worse outcome. Maximum score: 90, Minimum score: 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition: fat mass</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Body composition assessed by mean of bioimpedance analysis: fat mass in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition: fat free mass</measure>
    <time_frame>Change from baseline to 5 weeks after polyol/sucrose intake</time_frame>
    <description>Body composition assessed by mean of bioimpedance analysis: fat free mass in kg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Glucose Tolerance</condition>
  <condition>Body Composition</condition>
  <condition>Gastrointestinal Tolerance</condition>
  <arm_group>
    <arm_group_label>Sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 participants receive 25g sucrose per day during 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythritol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 participants receive 36g eryhtritol per day during 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eryhtritol</intervention_name>
    <description>Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks</description>
    <arm_group_label>Erythritol</arm_group_label>
    <other_name>E968-Erythritol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks</description>
    <arm_group_label>Sucrose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adolescents&#xD;
&#xD;
          -  Aged 14-18 years&#xD;
&#xD;
          -  Normal weight (BMI between 15th and 85th percentile for age and gender)&#xD;
&#xD;
          -  Minimum weight of 45kg&#xD;
&#xD;
          -  Regular sugar consumption &gt;25g/d&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe acute or chronic diseases&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Regular intake of prebiotics&#xD;
&#xD;
          -  Regular intake of probiotics&#xD;
&#xD;
          -  Regular intake of pro-/prebiotic foods&#xD;
&#xD;
          -  Antibiotics cure within 3 months preceding the present study&#xD;
&#xD;
          -  Substance abuse&#xD;
&#xD;
          -  Inability to follow procedures due to psychological disorders or insufficient&#xD;
             knowledge of project language (German)&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study.&#xD;
&#xD;
          -  Pre-existing regular consumption (&gt;1/week) of erythritol&#xD;
&#xD;
          -  Fructose-intolerance&#xD;
&#xD;
          -  Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction,&#xD;
             etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina K. Wölnerhanssen, PD. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Clara Research Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina K. Wölnerhanssen, PD. MD</last_name>
    <phone>+ 41 61 685 86 32</phone>
    <email>bettina.woelnerhanssen@claraspital.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Christin Meyer-Gerspach, PD. PhD</last_name>
    <phone>+41 61685 86 44</phone>
    <email>annechristin.meyergerspach@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Claraspital</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina K. Wölnerhanssen, PD. MD</last_name>
      <phone>+41 61 685 86 32</phone>
      <email>bettina.woelnerhanssen@claraspital.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythritol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

